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Abstract
MicroRNAs (miRNAs) are predicted to regulate approximately 30% of all human genes; however, only a few miRNAs have
been assigned their targets and specific functions. Here we demonstrate that miR-24, a ubiquitously expressed miRNA, has
an anti-proliferative effect independent of p53 function. Cell lines with differential p53 status were used as a model to study
the effects of miR-24 on cell proliferation, cell cycle control, gene regulation and cellular transformation. Overexpression of
miR-24 in six different cell lines, independent of p53 function, inhibited cell proliferation and resulted in G2/S cell cycle
arrest. MiR-24 over expression in cells with wt-p53 upregulated TP53 and p21 protein; however, in p53-null cells miR-24 still
induced cell cycle arrest without the involvement of p21. We show that miR-24 regulates p53-independent cellular
proliferation by regulating an S-phase enzyme, dihydrofolate reductase (DHFR) a target of the chemotherapeutic drug
methotrexate (MTX). Of interest, we found that a miR-24 target site polymorphism in DHFR 39 UTR that results in loss of miR-
24-function and high DHFR levels in the cell imparts a growth advantage to immortalized cells and induces neoplastic
transformation. Of clinical significance, we found that miR-24 is deregulated in human colorectal cancer tumors and a subset
of tumors has reduced levels of miR-24. A novel function for miR-24 as a p53-independent cell cycle inhibitory miRNA is
proposed.
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Introduction
MicroRNAs (miRNAs) are small non-coding RNAs, processed
from longer transcripts by Drosha and Dicer, that mostly bind to
the 39 untranslated regions (39UTR) of target genes and inhibit
gene expression translationally and/or by destabilizing the target
mRNA [1–5]. As miRNA expression is altered in many human
diseases, including cancer, the discovery of miRNAs has added an
entirely new dimension to antitumor therapeutic approaches [6].
Although a few miRNAs are overexpressed in cancer and seem to
function as oncogenes themselves (miR-17-92, miR-155), a greater
number of miRNAs have been shown to be down-regulated in
cancer and have the potential to act as tumor suppressors (i.e., Let-
7, miR-15/miR-16, miR-1/miR-206, miR-29, miR-124, miR-
143/miR-145) [7–9]. Hence miRNAs are differentially expressed
in many cancers and play a critical role in oncogenesis [7].
Although miRNAs have been predicted to regulate approxi-
mately 30% of all human genes, few miRNAs have been assigned to
their target mRNAs and specific functions [10]. MiR-24 is an
abundant miRNA and is well conserved between various species
(Fig. S1). MiR-24 is expressed in normal tissues such as adipose
tissue,mammarygland,kidneyandindifferentiatedskeletalmuscles
[11]. MiR-24 is found to be upregulated in differentiated cells. High
levels of miR-24 have been reported during post-mitotic differen-
tiation of hematopoietic cell lines [12], during thymic development
to naive CD8T cells [13] and during myoblast and neuronal
differentiation [14,15]. MiR-24 was also found to be upregulated
during the stationary phase of growth in CHO-K1 cells [16], and in
sodium butyrate differentiated embryonic stem cells [17]. MiR-24 is
also deregulated in Hodgkin lymphoma cell lines [18], and
inhibition of miR-24 in Hela cells markedly increased cell growth
[19]. MiR-24 also plays a role in erythropoiesis by regulating ALK4
and in replicative senescence by regulating p16 [20,21].
MiR-24 clusters with two other miRNAs, miR-23 and miR-27,
onchromosome 9 (cluster-1:miR-23b,miR-27bandmiR-24-1)andon
chromosome 19 (cluster-1: miR-23a, miR-27a and miR-24-2).
Deregulations at both sites were found to be associated with CLL
[9]. Since miR-24 is associated with differentiation, we explored the
role of miR-24in cellular transformation. We have previously shown
that miR-24 has a target site in the 39UTR of DHFR mRNA and a
PLoS ONE | www.plosone.org 1 December 2009 | Volume 4 | Issue 12 | e8445miR-24-SNP results in loss of miR-24-mediated inhibition of DHFR,
in MTX resistance, and is associated with an increase in DHFR
mRNA and protein [22]. A recent report also showed that miR-24
suppressed the expression of cell cycle control genes E2F2 and Myc
via binding to 39-UTR miRNA recognition elements [23].
In this study we used mutant and wild type p53 cell lines to study
the effects of miR-24 on cell proliferation and cell cycle control and
their mechanisms of regulation. We demonstrate that miR-24
regulates cellular proliferation, independent of p53 function, by
regulating DHFR expression. Of interest, we found that a miR-24
target site (TS) SNP 829CRT (hereafter referred as miR-24-TS-SNP)
in the DHFR 39 UTR results in loss of miR-24-function and high
DHFR levels in the cell, and imparts a growth advantage to immor-
talized cells and induces neoplastic transformation. Of possible clinical
significance, we find that miR-24 is deregulated in human colorectal
cancers, and subsets of tumors have reduced levels of miR-24.
Results
MiR-24 overexpression, independent of p53-function,
inhibits anchorage dependent cellular proliferation and
induces G2/S arrest
MiR-24is a highly conservedmiRNA amongspecies (Fig. S1). To
assess the functional significance of miR-24, we evaluated its effect
on cellular proliferation using six different cancer cell lines; four
human colon cancer cell lines [HCT-116 (wt-p53), HCT-116 (null-
p53), RKO (wt-p53) and HT-29 (mut-p53)] and two human
osteosarcoma cell lines [U2OS (wt-p53) and MG63 (null-p53)]. A
nonspecific miR was used as a negative control. Overexpression of
miR-24 suppressed cellular proliferation in all of the cell lines
independent of p53 status (Fig. 1A–G) (p,0.05, standard deviations
are plotted as error bars on the graph). The nonspecific control miR
had no effect on cellular proliferation, suggesting that miR-24
mediated inhibition of cellular proliferation is miR-24-specific.
We next determined if the effect of miR-24 on cellular
proliferation was related to cell cycle control. The effect of miR-24
on the cell cycle was analyzed by flow cytometry using HCT-116
(wt-p53) and HCT-116 (null-p53) cells transfected with a nonspe-
cific control miR or miR-24. MiR-24 increased the G2-S ratio in both
colorectal cancer cell lines (Fig. 2A, B). This finding, together with
thecell proliferation results (Fig.1),confirmed that miR-24mediated
inhibition of the cell-cycle is independent of p53 function.
MiR-24 overexpression affects cell cycle control genes
Induction of the p53-dependent cell cycle checkpoint control
gene p21 triggers cell cycle arrestat both G1 and G2 phases [24]. To
further analyze the cell cycle control genes involved in miR-24
overexpression, we analyzed p53 and p21 expression by immuno-
blotting in HCT-116 (wt-p53), U-2OS (wt-p53) and HCT-116 cells
(null-p53) (Fig. 2C–E). Ectopic expression of miR-24 significantly
increased the expression of p53 protein and p21 protein levels in
HCT-116 (wt-p53) cells (Fig. 2C). MiR-24 overexpression also
Figure 1. MiR-24 inhibits anchorage-dependent cell proliferation independent of p53 status in six different cancer cell lines. (A)
Morphological changes after the non-specific control-miR and miR-24 over expression in HCT-116 (wt-p53) is demonstrated. (B–G) Six different cancer
cell lines, with or without functional p53, were transfected with control miR (neg) or miR-24 and cell number was determined. Upon miR-24
transfection cell proliferation was inhibited approximately from 30% to 65% at day 5 as compared to the control (p,0.05, standard deviations are
plotted as error bars on the graphs). Of interest, regardless of the p53 status of a cell, miR-24 inhibited cell proliferation.
doi:10.1371/journal.pone.0008445.g001
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line (Fig. 2D). In contrast, a nonspecific-miR (neg) and oligofecta-
min (oligo) did not cause an increase in expression of p53 or p21
(Fig. 2C, D), suggesting that miR-24-mediated induction of p53 and
p21 is specific to miR-24 expression. However, in the HCT-116 cell
line that lacked the p53 gene, p21 was not induced (Fig. 2E),
indicating that in the absence of p53 function, miR-24 can still
induce cell cycle arrest without the involvement of p21.
MiR-24 regulates dihydrofolate reductase, a gene
associated with cell proliferation, independent of p53
function
DHFR is an S-phase specific enzyme and its levels in the cell are
associated with cellular proliferation [25]. Inhibition of DHFR
activity by methotrexate affects tumor cell proliferation both in
vitro and in cancer patients. MiR-24 has a target site on DHFR 39-
UTR [22]. We reasoned that miR-24-mediated down regulation of
DHFR may explain the anti-proliferative effect conferred by miR-
24 expression. To confirm this hypothesis, a miR-24 precursor was
transfected into cells of varying p53 function: HCT-116 (wt-p53),
U2-OS (wt-p53), and HCT-116 (null-p53). A nonspecific miR was
used as a negative control. DHFR siRNA was used as a positive
control. The expression of DHFR protein was analyzed using
Western blotting (Fig 3A–C). Overexpression of miR-24 clearly
decreased the expression of DHFR protein, with a potency that
was comparable to control DHFR-siRNA, independent of the
presence of functional p53. We also analyzed the expression level
of DHFR mRNA using real-time qRT-PCR analysis in two cell
lines. There was no reduction in DHFR mRNA expression
associated with miR-24 overexpression, whereas the decreased
expression of DHFR by siRNA was clearly caused by mRNA
degradation (Fig 3D, E). Thus, the miR-24 suppression of DHFR
Figure 2. MiR-24 induces a p53 independent G2-cell cycle arrest. (A, B) The bar graphs show the relative quantity of G1/S and G2/S ratio
between the non-specific miRNA (negative control) and miR-24 transfected cells. MiR-24 transfection induced a G2-cell cycle arrest. (C, D) miR-24
increases the expression of cell cycle control genes p53 and p21 in HCT 116 (wt-p53) and U-2 OS cells as determined by Western blotting. (E) In p53
null HCT-116 cells, independent of p21, miR-24 inhibited the G2 arrest (B and E).
doi:10.1371/journal.pone.0008445.g002
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independent of p53 status.
MiR-24 overexpression induces methotrexate resistance
Generally, MTX treatment inhibits proliferation of rapidly
dividing cancer cells without having a limited effect on the
proliferation of differentiated cells. As MiR-24 transfection has
been shown to induce differentiation in cells, we anticipated that
miR-24 overexpression would confer resistance to antiproliferative
drugs such as MTX. To test this hypothesis the effect of miR-24
overexpression on MTX resistance was tested. We used HCT-116
(wt-p53) cells transfected with a miR-24 mimic or non-specific
miRNA, or siRNA against DHFR. MTX cytotoxicity was
performed using previously published methods [22]. We observed
that transfection of miR-24 induced MTX resistance in HCT-116
cells, whereas cells transfected with siRNA specific to DHFR or
control miRNA were sensitive to MTX as compared to miR-24
transfected cells (Fig. 3F). Since miR-24 overexpression is
associated with differentiation (see introduction for detail) (Fig. 1
and 4), we suggest that the slow growth and differentiation caused
by miR-24 overexpression contributes to MTX resistance.
Overexpression of miR-24 down regulated DHFR
expression, reduced anchorage-dependent growth, and
induced differentiation-like morphological changes in a
colorectal cancer cell line
WequantitatedDHFRproteinlevels,morphologicalchanges,and
anchorage-dependent growth upon transfection of a siRNA specific
to DHFR and miR-24. MiR-24 overexpression down regulated
DHFR levels by approximately six fold as compared to Oligofecta-
mine alone transfected cells (Fig. 4A), and conferred a morphological
change resembling a differentiation-like phenotype in a colorectal
cancer cell line (HCT-116-wt-p53). The differentiation-like morpho-
logical change was not observed in HCT-116 cells transfected with
siDHFR and Oligofectamine alone (Cont) (Fig. 4B). Since
differentiation markers for colorectal cancer cells are not well
established, following miR-24 transfection we used light-microscopy
to quantitate the morphological changes in HCT-116 cells [34].
AlthoughmiR-24transfectionreducedHCT-116cell-proliferationby
70% (mostly cytotoxic effect), approximately 12% of the total
transfected cells and 38% of the total surviving cells showed
morphological changes that resembled differentiation (Fig. 4C).
These morphological changes were observed in all six cancer cell
lines tested, indicating these were independent of p53 function (data
not shown). There are many reports that demonstrate that miR-24
over expression is associated with a differentiated phenotype (see
introduction for detail). However, further studies are required to
confirm this observation in colorectal cancer cells by well
characterizing and establishing differentiation markers, which is an
activeareaofresearchinthelaboratory.Ofinterest,wealsoobserved
that over expression of a DHFR specific siRNA (siDHFR) down-
regulated DHFR levels by threefold as compared to Oligofectamine
alone transfected cells (Fig. 4A), and also reduced anchorage-
dependent growth of the HCT-116 colorectal cancer cell line by
approximately two fold (Fig. 4D); these data suggest that changes in
DHFR levels are directly associated with cell proliferation.
A miR-24 target site SNP in dihydrofolate reductase
39UTR confers an ability on immortalized cells to form
foci and growth in anchorage-independent fashion
DHFR is an S-phase enzyme and its levels are associated with cell
proliferation. We demonstrated earlier that a miR-24 target site SNP
829CRT( miR-24-TS-SNP)i nt h eD H F R3 9 UTR results in DHFR
overexpression due to loss of miR-24 function (22). We next tested
whether cells expressing a mutant miR-24-target site allele (CRT)
that over expresses DHFR provides cells with a growth advantage.
Figure 3. MiR-24 regulates cell proliferation by regulating DHFR levels, independent of p53 status. (A–C) miR-24 over-expression down-
regulated DHFR protein levels in three cancer cell lines independent of p53 function; in colon cancer HCT 116 (wt-p53) (A), osteosarcoma cell line U2-
OS (wt-p53) (B), and HCT-116 (null-p53) cancer cell lines (C). Oligofectamine alone (oligo) and non-specific miRNA (neg) were used as the negative
controls. siRNA specific against DHFR (siDHFR) was the positive control. (D–E) The levels of DHFR mRNA in HCT-116 and U-2 OS cells were determined
by real time qRT-PCR analysis, GAPDH was used as an internal standard for normalization (data are shown as mean6SD. *, P,0.05). (F) miR-24 not
only inhibited cell growth but also induced MTX resistance in a HCT-116 colorectal cancer cell line.
doi:10.1371/journal.pone.0008445.g003
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containing the wt 39UTR, or DHFR cDNA with the miR-24-TS-SNP
in the DHFR 39UTR. The miR-24-TS-SNP expressing cells had on
average a nineteen-fold increase in DHFR mRNA, and four to five
fold increase in levels of DHFR protein as compared to wild type
DHFR expressing cells [22]. We found that cells overexpressing
DHFR (.fourfold) (Fig. 5A) due to the miR-24-TS-SNP in the DHFR
gene formed more colonies as compared to wt and vector alone cells
(Fig. 5B, C). Of interest, the cells that overexpressed DHFR were
morphologicallydistinctfromthewtandthevectoralonecontrolcells
(Fig. 5B). The colonies formed by the cells with the SNP resembled
foci formation in monolayer cultures, characteristic of transformed
cells. The wt and vector alone cells that expressed less DHFR grew in
a monolayer and morphologically resembled normal DG44 cells
under the microscope (Fig. 5B). Contact inhibition was lost in SNP
expressing cells, resulting in foci formation with an increase in satu-
ration density as compared to the vector control culture (Fig. 5B, C).
As a second test for the transformed phenotype we used a
colony formation assay in soft agar. The ability of wt, miR-24-TS-
SNP and vector alone expressing cells to form colonies was tested.
We found that the cells with the miR-24-TS-SNP formed more
colonies in soft agar and acquired an anchorage-independent
phenotype with a six to seven fold increased efficiency as
compared with the vector alone cells and three fold more than
the cells that overexpressed wt DHFR with a wt 39 UTR (Fig. 5D).
Furthermore, to confirm that transformation was due to high
levels of DHFR, we next explored the effect of DHFR knock down
in the miR-24-TS-SNP expressing cells using a siRNA specific to
DHFR. Transfection of the DHFR-specific siRNA in miR-24-TS-
SNP expressing cells reduced the soft agar colony forming ability of
the cells to threefold (Fig. 5E), suggesting that anchorage
independent growth was specific to increased DHFR expression.
We next tested if overexpressed DHFR due to the miR-24-TS-
SNP can also induce anchorage independent growth in two
additional rodent cell lines (NIH3T3 cells and RK3-rat kidney
cells) and human breast epithelial MCF10A cells, in addition to
CHO cells. All three cell line are immortalized but not
transformed. The wt DHFR, miR-24-TS-SNP and vector alone
constructs were stably transfected into the three cell lines. All three
cell lines overexpressing DHFR (.5-fold) formed more colonies in
soft agar than the wt-expressing clones. No soft agar colonies were
observed in the cells transfected with the vector alone (Fig. 5F–H,
Table S1). Therefore, cells transfected with DHFR mRNA
containing the miR-24-TS-SNP induced anchorage independent
growth in three immortalized rodent cell lines (CHO, NIH3T3
and RK3) and an immortalized human cell line (MCF-10A).
Figure 4. Overexpression of miR-24 down regulated DHFR expression, reduced anchorage-dependent growth, and induced
morphological changes resembling differentiation. (A) DHFR protein levels were down regulated upon over-expression of DHFR specific
siRNA (siDHFR) (by three fold) and miR-24 (by six fold). (B) miR-24 over expression conferred morphological changes that resembled differentiated in a
colorectal cancer cell line (HCT-116-wt-p53). The differentiated-like morphological changes were not observed in HCT-116 cells transfected with
siDHFR and oligofectamine alone (Cont). (C) Due to a lack of well established differentiation markers, the morphological changes in miR-24
transfected cells were quantitated by light microscopy. Although miR-24 transfection resulted in approximately 70% reduction in cell proliferation,
approximately 12% of the total transfected cells, and 38% of total surviving cells, showed a differentiation-like phenotype. (D) Of interest, siRNA
specific to DHFR that down regulated DHFR levels in the cells by threefold also reduced anchorage-dependent growth of the HCT-116 colorectal
cancer cell line, suggesting that DHFR levels in the cell are associated with cell proliferation (data are shown as mean6SD. *, P,0.05).
doi:10.1371/journal.pone.0008445.g004
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cells tumorigenic in vivo
We next inoculated the miR-24-TS-SNP expressing NIH3T3
cells and vector alone expressing NIH3T3 cells subcutaneously on
to the back of nude mice and tumor formation was monitored. All
five animals that were inoculated with the SNP-expressing cells
with high DHFR levels (.5-fold) formed tumors, whereas vector
alone expressing cells did not form tumors (Fig. 5I). Hence DHFR
overexpression due to a miR-24-TS-SNP makes NIH3T3 cells
tumorigenic in nude mice.
MiR-24 is deregulated in human colorectal cancer tumors
and there is a subset of tumors with reduced levels of
miR-24
We investigated miR-expression in normal vs. cancer tissue
using miRNAMap-2 [26], and found that miR-24 levels were
frequently upregulated in normal but down regulated in cancer
cell line/tumor samples (Fig. 6A). Further we tested mir-24
expression in colorectal cancer tumors obtained from patients.
Total RNA was isolated from a total of 48 colorectal clinical
specimens (24 paired colorectal normal mucosa and tumor
samples), collected from patients undergoing surgical resection of
primary colorectal adenocarcinoma. MiR-24 levels were deter-
mined using q-RT-PCR (see methods for details). Of clinical
significance, we found that miR-24 was down regulated in 45% of
colorectal cancers as compared to the adjacent normal tissue.
Discussion
Since their discovery in the early 2000s, miRNAs and their
ability to regulate gene expression have revolutionized every
corner of biological inquiry. Understanding how miRNAs
orchestrate oncogenic progression may provide a better under-
standing of the disease and suggest novel therapeutic approaches
[6]. In this report we demonstrate that miR-24, an abundant
miRNA that is expressed at high levels in differentiated cells, has
an anti-proliferative effect and mediates inhibition of the cell cycle
Figure 5. A loss-of-function miR-24 target site SNP contributes to cellular transformation. (A) The miR-24-TS-SNP (829CRT) expressing
CHO-DG44 cells over-expressed DHFR [22]. (B–C) DHFR over expression in CHO-DG44 cells due a loss of miR-24 function results in an increase in
colony forming ability and (D) show anchorage-independent growth in semi solid agar as compared to vector alone expressing cells (p-value.0.05)
(Soft agar colony-forming assay is abbreviated as SAC). (E) Transfection of a siRNA specific to DHFR reduced the ability of miR-24-TS-SNP expressing
cells to form soft agar colonies by threefold. (F-H) miR-24-TS-SNP expression in a human cell line - MCF10A (G) and two rodent cell lines - NIH3T3 (H)
and RK3 (see Table S1) resulted in more soft agar colony formation as compared to the cells expressing the vector alone and DHFR with wt 39UTR. (I)
DHFR overexpression due to the miR-24-TS-SNP renders NIH3T3 cells tumorigenic when transplanted in nude mice.
doi:10.1371/journal.pone.0008445.g005
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gene associated with cell proliferation, independent of p53
function. We demonstrate that a loss of function-miR-24 target
site polymorphism in the DHFR 39UTR induces anchorage-
independent growth in vitro and renders immortalized cells
tumorigenic in nude mice. Of clinical significance, miR-24 is
deregulated in colorectal cancers from patients; 45% of the
patients tested had down regulated miR-24 expression in colorectal
cancers as compared to the adjacent normal tissue. These data
support the notion that miR-24 functions as a p53-independent
anti-proliferative miRNA and reexpression of miR-24 may
constitute a novel approach to arrest tumor development, at least
in part by modulating DHFR expression.
We previously demonstrated that a loss of miR-24 function
polymorphism results in methotrexate resistance as a conse-
quence of increased levels of DHFR mRNA and protein due to
loss of translational regulation [22]. Of interest, we observed
that over expression of miR-24 rendered cells more resistant to
MTX due to reduced cellular proliferation. Over expression of
miR-24 may affect expression of other proteins while the miR-24-
TS-SNP phenotype has a more DHFR-specific effect. The loss of
miR-24 function target site polymorphism that results in DHFR
over expression, increased cell proliferation and transformed
immortalized cells suggests a novel role for miR-24 as a tumor
suppressor miRNA. Alternatively it can be anticipated that a
miR-24-TS-SNP that can create miRNA-mediated repression of
tumor-suppressor genes may also have an ability to transform
the cell [27].
DHFR is preferentially synthesized in proliferating cells and is
an essential enzyme for DNA synthesis and repair. High DHFR
levels were found in human brain tumors, in hypoplastic
myelodysplasia and in cisplatin-resistant human colon carcinoma
cells [28–30]. Human-like DHFR was found to be encoded in
Kaposi’s sarcoma-associated herpes virus (KSHV), which is known
to cause Kaposi’s sarcoma and other hematological malignancies
[31]. DHFR gene amplification was also correlated with the
metastatic potential of rat adenocarcinoma cells [32]. Similarly,
our work shows that over expression of DHFR leads to increased
cellular proliferation and transformation of immortalized cells, and
is regulated, at least in part, by miR-24 miRNA. Transfection of
DHFR cDNA and selection of cells with high DHFR levels also
transformed immortalized cells in vitro and rendered them
tumorigenic in vivo [25].
MiR-24 regulates the G2/S phase of the cell cycle indepen-
dent of p53 and p21 function, which in part can be explained by
its ability to regulate DHFR translation. However, miRNAs
have the ability to up-regulate or down-regulate several essential
cellular enzymes and push the cell into cycle. It has been
reported recently that miR-24 can suppress the expression of
E2F2, Myc and other cell cycle control genes and trigger cell
cycle arrest [23]; however cell lines used were either mutant or
p53 deleted [23]. In this study, we demonstrate that p21 levels
Figure 6. MiR-24 is deregulated in human colorectal cancer tumors. (A) We investigated the miR-24 expression, using miRNAMap-2 [20], in
normal vs. cancer tissue and found that miR-24 is expression was clearly detectable in normal cell lines/tissues but is down regulated in cancer cell
line/tumor samples, as compared to the control cells/tissues (column 1, miR-24-1; column 2, miR-24-2). (B) Mir-24 expression was assayed by Q-RTPCR
in human colorectal specimens (24 paired colorectal normal mucosa and tumor samples) collected from patients undergoing surgical resection of
primary colorectal adenocarcinoma.
doi:10.1371/journal.pone.0008445.g006
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presence of p53.
Expression of DHFR in S-phase is required for DNA
biosynthesis; this is consistent with the finding that the expression
level of miR-24 was high in G1 and G2/M but low in S phase [23].
Deregulations of both miR-24 sites were found to be associated
with CLL [8]. We demonstrate that miR-24 levels are deregulated
in tumors obtained from colorectal cancer patients. Taken
together these data indicate that miR-24 is an important regulator
of cell proliferation and reexpression of miR-24 may have
therapeutic anticancer value.
The miR-24-TS-SNP 829CRT occurs at a 14.2% allelic
frequency in the Japanese population, and may predispose cells
for cellular transformation following other events in a cell.
MiRNA-polymorphisms (miR-polymorphisms or miRSNPs) are
a novel class of functional polymorphisms present in the human
genome [33,34]. Cumulative evidences now suggest that genetic
variations in miRNAs and are involved in the progression and
prognosis of diseases, including neurological disorders and
cardiovascular disorders and cancer [35,36]. By affecting miRNA
target function, miR-polymorphisms can potentially affect the
expression of several downstream genes and related pathways in a
cell [36]. We demonstrate that a loss of miR-24 function-SNP that
results in DHFR over expression and MTX resistance, following
other events in a cell, can also predispose immortalized cells for
transformation. Further inquiry in to related ethnic groups as to its
presence, and its effect on treatment outcome and or toxicity will
be of importance.
In summary we propose a novel role for the miRNA miR-24 as
an anti-proliferative miRNA, independent of p53 function, by
showing that it targets a pro-proliferation gene DHFR. Loss of
miR-24 function, due to a SNP in the 39UTR of DHFR leads to
overexpression of DHFR mRNA and protein and transformation
of immortalized cells.
Materials and Methods
Ethics Statement
Patient consent was obtained in writing according to institu-
tional regulations. The studies were approved by the Ethics
Committee of the University of Ulm (Ulm, Germany) and by the
University of Medicine and Dentistry of New Jersey (UMDNJ)
Institutional Review Board (IRB) in writing [IRB # 0220080331,
written consent was obtained on 1/22/09].
Cell culture and growth media
The human osteosarcoma cell lines U-2 OS, MG63, RKO and
HT-29 were obtained from the American Type Culture Collection
(ATCC). The human colon cancer cell lines HCT 116 (wt-p53)
and HCT 116 (null-p53) were a gift from Professor Bert Vogelstein
(The Johns Hopkins University) and were maintained in McCoy’s
5A medium (Gibco Laboratories) supplemented with 10%
dialyzed fetal bovine serum (HyClone Laboratories). MTX was
purchased from Sigma-Aldrich. NIH/3T3, Rat kidney cells (RK3)
were purchased from ATCC and grown in Dulbelcco’s modified
Eagle’s medium (DMEM) with 10% fetal bovine serum (FBS), 1%
penicillin/streptomycin, 1% l-glutamine (Gibco-BRL).
Transfections of miR-24 and siRNAs
RKO, HT-29, U2-OS, MG63, HCT-116 (wt-p53) and HCT-
116 (null-p53) cells (2610
5) were plated in six-well plates and
transfected with 100 nM of either miR-24 or non-specific miRNA
(Ambion) after 24 h by Oligofectamine (Invitrogen) according to
the manufacturer’s protocols. siRNA against DHFR was pur-
chased from Dharmacon and transfected with Oligofectamine
(Invitrogen) at a final concentration of 100 nM.
RNA Isolation
Total RNA, including miRNA, was isolated from the miR-24
transfected cell lines (24 h after transfection) and from clinical
colorectal cancer samples using TRIzol reagent, according to the
manufacturer’s instructions (Invitrogen).
Real Time qRT-PCR Analysis
cDNA synthesis was carried out with the High Capacity cDNA
synthesis kit (Applied Biosystems). For mRNA expression the PCR
primers and probes for DHFR and internal control gene GAPDH
were purchased from Applied Biosystems. Real-time quantitative
reverse transcription-PCR (qRT-PCR) analysis was performed on
an Applied Biosystems 7500 Real-Time PCR System. The
miRNA sequence-specific RT-PCR primers for miR-24 and
endogenous control RNU6B were purchased from Ambion. The
gene expression DCT values of miRNAs from each clinical sample
were calculated by normalizing with internal control RNU6B and
relative quantitation values were plotted. Sample with the lowest
DCT value of miR-24 was set as 1 to generate relative expression
values using 2
2ddCT method [37].
Cell Cycle Analysis
HCT 116 (wt-p53) and HCT 116 (null-p53) cells were
transfected with miR-24 mimic, non-specific miRNA or siRNA
against DHFR described as above. At 36 h after transfection, cells
were harvested and resuspended at 0.521610
5 cells/ml in
modified Krishan buffer containing 0.1% sodium citrate and
0.3% NP-40 and kept at 4uC. Before being analyzed by flow
cytometry, cells were treated with 0.02mg/ml RNase H and
stained with 0.05mg/ml propidium iodide (Sigma).
Western blot analysis and antibodies
At 48 h after transfection with miR-24 mimic or non-specific
miRNA, the cells were scraped and lysed in RIPA buffer (Sigma).
The primary antibodies included mouse anti-DHFR mAb (1:250,
BD Bioscience), mouse anti-p53 mAb (1:1000, DO-1), mouse anti-
p21 mAb (1:1000, F-5), and mouse anti-a-tubulin mAb (1:1000,
TU-02) from Santa Cruz Biotechnology. Oligofectamine alone
and non-specific miRNA were used as the negative controls.
siRNA against DHFR was used as the positive controls. Bands
were quantitated using National Institute of Health’s ImageJ
software.
MTX Chemosensitivity
HCT 116 (wt-p53) cells were plated in 96-well plates at 1610
3
cells/well in triplicate after transfected with miR-24 mimic, non-
specific miRNA, or siRNA against DHFR in 100 ml of medium.
Twenty-four hours later, MTX in 100 ml medium ranged from
10–200 nM was added, and incubated for 72 h. WST-1 (Roche
Applied Science) was added to each well (10 ml). After 2 h
incubation, absorbance was measured at 450 and 630 nm
respectively. Non-specific miRNA was used as the negative
control, and siRNA specific for DHFR was positive controls.
Cloning and site directed mutagenesis cell transfections
and generation of stable clones
Wild type DHFR was cloned in a pCDNA3.1 vector and the
829CRT mutation was created using QuickChange site directed
mutagenesis kit (Stratagene, La Jolla, CA) as described previously
[22]. The vector alone wt and mutant constructs were transfected
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cells were transfected, selected with G418, and were picked and
expanded as cell lines [22].
Growth, morphological changes and anchorage-
independent growth assays
For cell proliferation analysis on the six cancer cell lines was
performed by plating the cells in 96-well plates in triplicate at
1610
3 cells/well after transfection with miR-24 mimic, non-
specific miRNA, or siRNA against DHFR (n=3). Cells were
cultured for 24, 48, 72, 96 h. The absorbance at 450 and 630 nm
was measured after incubation with 10 ml of WST-1 for 2 h.
Differentiation-like morphological changes in HCT-116 cells upon
miR-24 transfection was quantitated by light-microscopy [38].
Anchorage-independent growth was carried out by plating 5610
4
cells per well in 6-well plates in triplicates [39]. After 4–6 weeks
incubation the cells were fixed with methanol and acidic acid
solution (10%), and stained with ethanol (20%), crystal violet
(0.4%); the colonies were scored and large and small colonies were
counted. The growth of the clones was assayed by platting 50,000
cells per well in 12-well plates in triplicates and counted at 1–6
days.
Xenograft studies in nude mice
Tumorigenicity of DHFR over expressing NIH3T3 and RK3
cells was assayed by tumor formation in nude mice. Cells
expressing DHFR and vector alone constructs were expanded
for two passages without selection. Ten million cells in a total
volume of 100ml in growth medium were injected subcutaneously
into the backs of 5 to 6-week-old NCR nu/nu mice (Taconic Farms
Inc, USA). The growths of tumors were followed three times
weekly after the inoculation.
Clinical Samples
A total of 48 snap-frozen colorectal patient specimens were
selected (24 paired colorectal normal mucosa and tumor samples).
These patients had undergone surgical resection of primary
colorectal adenocarcinoma at the Department of Visceral and
Transplantation Surgery, University of Ulm, Germany. The
colorectal cancer studies were approved by the Ethics Committee
of the University of Ulm (Ulm, Germany) and by the University of
Medicine and Dentistry of New Jersey (UMDNJ) Institutional
Review Board (IRB) in writing [IRB # 0220080331, written
consent was obtained on 1/22/09]. Patient consent was obtained
in writing from every patient according to the institutional
regulations. The characteristics of these patients are described as
previously [40]. RNA was isolated using the same method
described above (via supra).
Statistical analysis
All experiments were repeated at least twice. Statistical
significance was evaluated by Student’s t test (two tailed)
comparison between two groups of data. Asterisks indicate
significant differences of experimental groups compared with the
corresponding control condition. Statistical analysis was done
using GraphPad Prism software (GraphPad, Inc.). Variance ratio
test (F-test) was used to compare the variances of miR-24 levels in
normal vs cancer tissue. The statistically significant difference in
expression level between tumor and normal tissues was calculated
using a paired Wilcoxon test, and the statistical analysis was
performed by MedCalcH 10.0.2 (MedCalc software). Differences
were considered statistically significant at p,0.05.
Supporting Information
Figure S1 MiR-24 precursor and it’s conservation. A) miR-24
stem-loop precursor is shown (B) miR-24 are well conserved
among species, from mouse to humans.
Found at: doi:10.1371/journal.pone.0008445.s001 (1.24 MB TIF)
Table S1 Anchorage independent growth ability of miRSNP
expressing cells in three different cell types.
Found at: doi:10.1371/journal.pone.0008445.s002 (0.03 MB
DOC)
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